Serine protease inhibitors as anti-hepatitis C virus agents.

Abstract

Approximately 3% of the worldwide population (i.e., more than 170 million people) are chronically infected with the hepatitis C virus (HCV). An estimated 20% of these patients will develop liver cirrhosis within a mean of 20 years, and 2-5% of cirrhotic patients will die of end-stage liver disease or hepatocellular carcinoma. The currently approved… (More)
DOI: 10.1586/eri.09.30

Topics

  • Presentations referencing similar topics